Gf Fund Management Co. Ltd. Bei Gene, Ltd. Transaction History
Gf Fund Management Co. Ltd.
- $5.85 Trillion
- Q4 2025
A detailed history of Gf Fund Management Co. Ltd. transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Gf Fund Management Co. Ltd. holds 617 shares of BGNE stock, worth $139,880. This represents 0.0% of its overall portfolio holdings.
Number of Shares
617
Previous 723
14.66%
Holding current value
$139,880
Previous $246 Million
23.9%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding BGNE
# of Institutions
300Shares Held
30.5MCall Options Held
147KPut Options Held
195K-
Baker Bros. Advisors LP New York, NY8.8MShares$1.99 Billion16.25% of portfolio
-
Primecap Management CO Pasadena, CA5.08MShares$1.15 Billion0.91% of portfolio
-
Capital International Investors Los Angeles, CA5.05MShares$1.14 Billion0.19% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.63MShares$370 Million0.06% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E91.03MShares$234 Million7.05% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $23.5B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...